Condition

Achilles Tendinopathy: Options and What the Evidence Actually Shows

Midportion and insertional Achilles disease need different load plans.

Anatomy and clinical context

Achilles tendinopathy is a load-capacity problem. Eccentric and heavy-slow resistance programs are first-line.

Injections near the tendon carry rupture risk with steroids — choose carefully.

The standard-of-care ladder

Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.

  1. Step 1

    Conservative care

    Progressive loading, activity modification, heel lifts as needed.

  2. Step 2

    Injections

    Shockwave, PRP, and other orthobiologics in refractory midportion disease.

  3. Step 3

    Surgery

    Debridement or repair when nonoperative care fails.

Where cell therapy fits

Loading programs outperform most passive modalities. Orthobiologics are adjuncts.

  • Differentiate midportion vs insertional disease.
  • Avoid casual steroid into the tendon.
  • Banking is a separate longevity decision.

Selected citations

  • Shapiro 2017

    Shapiro et al. · AJSM (2017)

    BMAC vs saline in the same patient's other knee — no difference on primary outcomes.

Why dose and donor age change the picture

The trials that disappoint used unexpanded cells from older donors.

The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.

  1. 1

    Cells work at dose.

    A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.

  2. 2

    Potency is age-dependent, and it is a one-way door.

    Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.

  3. 3

    Expansion is what makes the bank a supply, not a souvenir.

    Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.

  4. 4

    The provider decides what happens next.

    We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.

Two next steps — equal weight

Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.